Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry
Jazyk angličtina Země Irsko Médium print
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
PubMed
30270071
DOI
10.1016/j.atherosclerosis.2018.08.008
PII: S0021-9150(18)31257-7
Knihovny.cz E-zdroje
- Klíčová slova
- Ezetimibe, Familial hypercholesterolemia, LDL-C goal attainment, LDL-Cholesterol, Statins, Treatment pattern,
- MeSH
- anticholesteremika škodlivé účinky terapeutické užití MeSH
- biologické markery krev MeSH
- časové faktory MeSH
- down regulace MeSH
- ezetimib terapeutické užití MeSH
- fenotyp MeSH
- genetická predispozice k nemoci MeSH
- genetické markery MeSH
- heterozygot MeSH
- hodnocení rizik MeSH
- hyperlipoproteinemie typ II krev farmakoterapie epidemiologie genetika MeSH
- inhibitory serinových proteinas terapeutické užití MeSH
- kardiovaskulární nemoci epidemiologie prevence a kontrola MeSH
- kombinovaná farmakoterapie MeSH
- LDL-cholesterol krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- PCSK9 inhibitory MeSH
- proproteinkonvertasa subtilisin/kexin typu 9 metabolismus MeSH
- průřezové studie MeSH
- registrace MeSH
- retrospektivní studie MeSH
- statiny terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
- Slovenská republika epidemiologie MeSH
- Názvy látek
- anticholesteremika MeSH
- biologické markery MeSH
- ezetimib MeSH
- genetické markery MeSH
- inhibitory serinových proteinas MeSH
- LDL-cholesterol MeSH
- PCSK9 inhibitory MeSH
- PCSK9 protein, human MeSH Prohlížeč
- proproteinkonvertasa subtilisin/kexin typu 9 MeSH
- statiny MeSH
BACKGROUND AND AIMS: Despite the high prevalence of familial hypercholesterolemia (FH) and available effective lipid-lowering therapy, most of the individuals with this disorder remain undiagnosed and undertreated. The aim of the PLANET registry was to assess the real-life attainment of low-density lipoprotein cholesterol (LDL-C) therapeutic target level in patients with heterozygous FH, to characterize prescribed lipid-lowering therapy with assessment of its efficiency according to the attainment of the target LDL-C level, and to characterize cardiovascular events observed in this patient population again in relation to LDL-C target level attainment. METHODS: PLANET registry was designed as a non-interventional, retrospective, cross-sectional, multicentre disease registry for adult patients with heterozygous FH in the Czech Republic and Slovakia. RESULTS: Overall, 1755 patients were enrolled at 32 sites specialized in FH treatment. 15.4% of patients attained the target LDL-C value. The proportion of patients with LDL-C goal achievement increased to 17.3% in the subgroup of patients receiving high-intensity statin therapy (54.6% of study population). Out of 55 patients receiving inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9), 61.8% reached the LDL-C treatment goal. Of all cardiovascular events reported, 14.0% occurred in patients attaining the LDL-C goal, while it was 86.0% in the not-at-target group. It was documented (p=0.004) that the longer is the patient in care at the specialized FH centre, the higher is the probability that he/she will attain the target LDL-C level. CONCLUSIONS: Although target LDL-C level attainment remains relatively low, the likelihood of LDL-C goal attainment increases with duration of specialized care.
Citace poskytuje Crossref.org
